MX2022004203A - Profarmacos de inhibidores de mieloperoxidasa. - Google Patents

Profarmacos de inhibidores de mieloperoxidasa.

Info

Publication number
MX2022004203A
MX2022004203A MX2022004203A MX2022004203A MX2022004203A MX 2022004203 A MX2022004203 A MX 2022004203A MX 2022004203 A MX2022004203 A MX 2022004203A MX 2022004203 A MX2022004203 A MX 2022004203A MX 2022004203 A MX2022004203 A MX 2022004203A
Authority
MX
Mexico
Prior art keywords
prodrugs
mpo
myeloperoxidase
inhibitors
methods
Prior art date
Application number
MX2022004203A
Other languages
English (en)
Spanish (es)
Inventor
Yan Zhang
Eric Strobel
Gene M Dubowchik
Allen B Reitz
Iv Joseph Theodore Lundquist
Melody A Mcwherter
Jeffrey C Pelletier
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of MX2022004203A publication Critical patent/MX2022004203A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
MX2022004203A 2019-10-10 2020-10-09 Profarmacos de inhibidores de mieloperoxidasa. MX2022004203A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962913417P 2019-10-10 2019-10-10
PCT/US2020/054896 WO2021072140A1 (en) 2019-10-10 2020-10-09 Prodrugs of myeloperoxidase inhibitors

Publications (1)

Publication Number Publication Date
MX2022004203A true MX2022004203A (es) 2022-07-04

Family

ID=75438074

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004203A MX2022004203A (es) 2019-10-10 2020-10-09 Profarmacos de inhibidores de mieloperoxidasa.

Country Status (11)

Country Link
US (1) US20240067651A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041735A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022552834A (cg-RX-API-DMAC7.html)
KR (1) KR20220080133A (cg-RX-API-DMAC7.html)
CN (1) CN114945573A (cg-RX-API-DMAC7.html)
AU (1) AU2020363903A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006381A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157260A1 (cg-RX-API-DMAC7.html)
IL (1) IL291891A (cg-RX-API-DMAC7.html)
MX (1) MX2022004203A (cg-RX-API-DMAC7.html)
WO (1) WO2021072140A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010902A (es) * 2020-03-05 2022-10-07 Biohaven Therapeutics Ltd Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa.
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012797A1 (en) * 1989-04-19 1990-11-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sulfer-containing xanthine derivatives as adenosin antagonists
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
WO2007069924A1 (en) * 2005-12-15 2007-06-21 Industrial Research Limited Deazapurine analogs of 4'-aza-l-nucleosides
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
NZ604423A (en) * 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
SG11202000086PA (en) * 2017-07-17 2020-02-27 Astrazeneca Ab Mpo inhibitors for use in medicine

Also Published As

Publication number Publication date
JP2022552834A (ja) 2022-12-20
AU2020363903A1 (en) 2022-03-24
CA3157260A1 (en) 2021-04-15
EP4041735A4 (en) 2023-11-22
IL291891A (en) 2022-06-01
KR20220080133A (ko) 2022-06-14
CN114945573A (zh) 2022-08-26
WO2021072140A1 (en) 2021-04-15
US20240067651A1 (en) 2024-02-29
BR112022006381A2 (pt) 2022-06-28
EP4041735A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
EP4245367A3 (en) Methods for treating cholestasis
ZA202204929B (en) Rimegepant for cgrp related disorders
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
MY207223A (en) Prodrug modulators of the integrated stress pathway
WO2019236775A8 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
MY155633A (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
EP4302764A3 (en) C17, c20, and c21 substituted neuroactive steroids and their methods of use
PH12021550443A1 (en) Pyridazinones and methods of use thereof
SG10201808063PA (en) Compositions for modulating ataxin 2 expression
MX2022002198A (es) Composiciones y métodos para modular el empalme y la expresión de proteínas.
MX2021002305A (es) Tratamiento de trastornos del higado.
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
MX2024010655A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2021000977A (es) Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
PH12021550671A1 (en) Prodrugs of cgrp antagonists
MX2019012086A (es) Composiciones y métodos para tratar o prevenir trastornos relacionados con la permeabilidad intestinal.
WO2023288332A3 (en) Genome editing compositions and methods for treatment of wilson's disease
EP4640698A3 (en) Antibodies to mucin-16 and methods of use thereof
MX2023005971A (es) Metodos y composicion para las modificaciones de kras.
WO2021100029A3 (en) Prodrugs of fulvestrant